Larimar Therapeutics Inc (fra:ZA71) Share Price

Company Profile

Business description
Larimar Therapeutics Inc is a clinical-stage biotechnology company focused on developing treatments for patients suffering from complex rare diseases using its novel cell penetrating peptide technology platform. Its flagship product candidate, nomlabofusp, is a subcutaneously administered recombinant fusion protein designed to deliver frataxin (FXN) to the mitochondria of patients with Friedreich's ataxia (FA), a rare genetic disease characterized by insufficient production of FXN. The company also plans to use its intracellular delivery platform to design other fusion proteins to target additional rare diseases characterized by deficiencies in intracellular bioactive compounds.
Contact
Three Bala Plaza East
Suite 506
Bala CynwydPA19004
USA
T: +1 844 511-9056
https://www.larimartx.com
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2026
Employees
71

Recommended

SpaceX has risen 50% from its IPO price to become the second-most-expensive stock under Morningstar’s coverage.

Tom Lauricella | 19 June 2026

Even as competition looks likely to build, the company remains a leading wide-moat business securely at the center of the AI ecosystem.

Brian Colello, CPA | 19 June 2026

Most Australians will end up owning SpaceX — whether they like it or not.

Tyger Fitzpatrick | 19 June 2026

Index	Last price	Change	% Change
All Ordinaries	9,047.30	25.90	-0.29%
CAC 40	8,421.14	46.84	-0.55%
DAX 40	24,985.82	40.98	-0.16%
Dow JONES (US)	51,564.70	72.15	0.14%
FTSE 100	10,363.27	36.43	-0.35%
HKSE	23,924.81	387.35	-1.59%
NASDAQ	26,517.93	496.28	1.91%
Nikkei 225	71,250.06	196.57	0.28%
NZX 50 Index	13,495.63	132.32	0.99%
S&P 500	7,500.58	80.48	1.08%
S&P/ASX 200	8,828.70	27.90	-0.32%
SSE Composite Index	4,090.48	17.59	-0.43%